OOIR: Observatory of International Research

Papers

(The median citation count of Current Opinion in Lipidology is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Editorial introductions	76
Familial hypercholesterolemia-Plus: is the metabolic syndrome changing the clinical picture of familial hypercholesterolemia?	63
Triglyceride-rich lipoproteins, remnant-cholesterol, and atherosclerotic cardiovascular disease	61
Alveolar macrophages: guardians of the alveolar lipid galaxy	57
Ups and downs in PCSK9 inhibition in the cardiovascular arena: a review	42
Genetic variation in apolipoprotein A-V in hypertriglyceridemia	42
Angiopoietin-like protein 8: a multifaceted protein instrumental in regulating triglyceride metabolism	37
The lipid-heart hypothesis from the Seven Countries Study of Cardiovascular Diseases	34
Oxidized LDL receptors: a recent update	32
Lipoprotein(a) and peripheral artery disease: contemporary evidence and therapeutic advances	26
Familial hypercholesterolemia: The nexus of endothelial dysfunction and lipoprotein metabolism in COVID-19	23
Implementation science and genetic testing for familial hypercholesterolemia	19
Universal screening for familial hypercholesterolaemia: how can we maximise benefits and minimise potential harm for children and their families?	18
Familial hypercholesterolemia in children and the importance of early treatment	17
Exosomes and lipid metabolism in metabolic and cardiovascular disorders	17
Lipid metabolism during pregnancy: consequences for mother and child	17
Nonalcoholic fatty liver disease: an update	16
Editorial introductions	16
A new SPRING in lipid metabolism	16
Nutrition and its impact on cardiovascular disease	15
Familial hypercholesterolemia in pregnancy	14
The need for national and international registries of patients with elevated lipoprotein(a)	14
Genetic determinants of pancreatitis risk in hypertriglyceridemia	14
The current state of apolipoprotein E in dyslipidemia	14
The intracellular chylomicron highway: novel insights into chylomicron biosynthesis, trafficking, and secretion	14

Editorial introductions	13
The complex pro-atherosclerotic role of lipoprotein(a): a multiplicity of cellular targets	13
From clinical development to real-world outcomes with inclisiran	13
High-density lipoprotein functionality, cardiovascular health, and patterns of alcohol consumption: new insights and future perspectives	12
Are the lipid-lowering effects of incretin-based therapies relevant for cardiovascular benefit?	12
APOE and familial hypercholesterolemia	12
ANGPTL3 and ApoC-III inhibitors for treating hypertriglyceridemia in context: horses for courses?	12
Inclisiran: present and future perspectives of a new effective LDL cholesterol-lowering agent	11
Evolving guidelines on lipoprotein(a)	11
Editorial introductions	10
Can small dense LDL cholesterol be estimated from the lipid profile?	10
Cardiomyocytes, sphingolipids and cardio myotoxicity	10
The expanding role of lyso-phosphatidylcholine acyltransferase-3 (LPCAT3), a phospholipid remodeling enzyme, in health and disease	9
The emerging role of fat-inducing transcript 2 in endoplasmic reticulum proteostasis and lipoprotein biogenesis	9
Distinct roles of size-defined HDL subpopulations in cardiovascular disease	9
Strategies for management of patients with elevated lipoprotein(a)	8
In the wake of the Scandinavian Simvastatin Survival Study trial	8
Newborn screening for lipid disorders	8
Beyond cholesterol: linking the conformation of apolipoprotein B to atherogenesis	8
Altered cardiovascular risk pattern of LDL cholesterol in older adults	7
Genetic testing for familial hypercholesterolemia	7
Pregnancy, cardiovascular health, and microchimerism	7
Circulating protein and lipid markers of early sepsis diagnosis and prognosis: a scoping review	7
Clinical associations between exercise and lipoproteins	7
Sphingosine-1-phosphate: metabolism, transport, atheroprotection and effect of statin treatment	6
Editorial introductions	6
A contemporary snapshot of familial hypercholesterolemia registries	6
Prevention of cardiometabolic diseases through dietary modifications	6
Genotype–phenotype correlation in a large cohort of pediatric patients with heterozygous and homozygous familial hypercholesterolemia	6
The feedback cycles between glucose, amino acids and lipids and alpha cell secretion and their role in metabolic fatty liver disease	6
The pathophysiology of excess plasma-free cholesterol	6
Navigating variants of uncertain significance in genetic dyslipidemia: how to assess and counsel patients	6
Dietary fat, telomere length and cognitive function: unravelling the complex relations	6
Lipidomics in gestational diabetes mellitus	5
Remnant cholesterol as a new lipid-lowering target to reduce cardiovascular events	5
Diagnosis of remnant hyperlipidaemia	5
Triglyceride-rich lipoprotein cholesterol and cardiovascular risk	5
Proprotein convertase subtilisin/kexin type 9-inhibition across different patient populations	5
The current landscape of prospective proteomics research into dementia using blood-based samples	5
Atherogenic low-density lipoprotein and cardiovascular risk	5
Predictors of cardiovascular risk in familial hypercholesterolemia	5
Resolution of apolipoprotein A1 and A2 proteoforms: their cardiometabolic correlates and implications for future research	5
Basic and translational evidence supporting the role of TM6SF2 in VLDL metabolism	5
Assessment of cardiovascular disease risk: a 2023 update	5
Translating guidelines into practice via implementation science: an update in lipidology	5
How should low-density lipoprotein cholesterol be calculated in 2022?	5
Understanding the ins and outs of lipoprotein (a) metabolism	5
Bempedoic acid for nonalcoholic fatty liver disease: evidence and mechanisms of action	5
Are Lipoprotein(a) levels decreased in insulin resistance and type 2 diabetes?	5
Recent lipoprotein(a) trials	5

Consensus and guidelines on lipoprotein(a) – seeing the forest through the trees	4
Complex actions of sodium glucose transporter-2 inhibitors on lipids, calcific atherosclerosis, and bone density	4
Established and potential cardiovascular risk factors in metabolic syndrome: Effect of bariatric surgery	4
Macrophage SR-B1 in atherosclerotic cardiovascular disease	4
Genetics of remnant cholesterol	4
Cholesteryl ester transfer protein inhibition: a pathway to reducing risk of morbidity and promoting longevity	4
Orticumab: the potential to harness oxidized LDL to reduce coronary inflammation with plaque-targeted therapy	4
Inflammation in atherosclerosis: a Big Idea that has underperformed so far	4
Regulation of cardiovascular calcification by lipids and lipoproteins	4
Novel therapeutic opportunities for familial lecithin:cholesterol acyltransferase deficiency: promises and challenges	4
Editorial introduction	4
Bempedoic acid: new evidence and recommendations on use	4
Lipidome and inflammation interplay: the role of diet in this relationship	3
G protein-coupled receptor 146: new insights from genetics and model systems	3
Circulating cell-free DNA and its association with cardiovascular disease: what we know and future perspectives	3
Editorial introductions	3
Proprotein convertase subtilisin/kexin type 9 inhibition after acute coronary syndrome or prior myocardial infarction	3
Ultra-processed foods and CKD: a review of evidence, limitations, and future directions	3
Editorial introduction	3
Editorial introductions	3
Macrophage cannibalism: efferocytosis in atherosclerosis	3
Cycling of metabolic states and metabolites as drivers of atherosclerosis	3
Editorial introductions	3
Editorial introduction	3
Lipoprotein (a) in familial hypercholesterolaemia	3
Inflammation and atherosclerotic cardiovascular disease: where do we go from here?	3
PCSK9-directed therapies: an update	3
Brain lipid metabolism: the emerging role of lipid droplets in glial cells	3
Proprotein convertase subtilisin/kexin type 9 as a drug target for abdominal aortic aneurysm	3